Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 EPS Loss of $0.08
Tweet
Share
E-mailGet Alerts CYCC Hot Sheet
Join SI Premium – FREE
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) reported Q2 EPS of ($0.08), $0.03 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $190 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lennar Corp. (LEN) Misses Q2 EPS by 1c
- MIND Technology (MIND) Misses Q1 EPS by 5c
- SailPoint Technologies Holdings (SAIL) Tops Q2 EPS by 1c, Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
